Class 5 (Live Case) - Eccentric and Ostial Lesions - Focus on Best Practices

Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the... Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial. Read more Show less

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate... Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages. Read more Show less

Nicolas Van Mieghem is the Clinical Director of Interventional Cardiology and Professor of... Nicolas Van Mieghem is the Clinical Director of Interventional Cardiology and Professor of Interventional Cardiology at the Thoraxcenter, Erasmus University Medical Center, Rotterdam. He obtained his medical degree and cardiology degree at the Catholic University of Leuven, Belgium. After subsequent Fellowships in interventional cardiology in at Ziekenhuis Oost-Limburg Genk, Belgium, Lenox Hill Hospital, New York, United States and Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands, he joined the senior staff of the department of interventional cardiology in the Thoraxcenter in February 2010. Professor Van Mieghem’s academic interest is in complex (calcified) coronary lesions, mechanical circulatory support and structural heart interventions. He obtained a PhD based upon his research in transcatheter valve therapies. Professor Van Mieghem is involved in the percutaneous coronary interventions and structural heart program. Professor Van Mieghem has published and co-authored over 400 scientific papers in peer-reviewed journals. He is principle investigator and steering committee member in multiple ongoing international trials evaluating various coronary and transcatheter valve technologies. He is a Fellow of the European Society of Cardiology and the American College of Cardiology. Read more Show less

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The... Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial. Read more Show less

James Spratt Professor of Interventional cardiology with a sub-speciality interest in complex... James Spratt Professor of Interventional cardiology with a sub-speciality interest in complex PCI, intravascular imaging and CTO. He is widely published within this area and has performed live case demonstrations globally. He has an interest in medical education and is the Founder of Optima Education. Read more Show less

Dr Julian Strange is a consultant interventional cardiologist at Bristol Heart Institute, UK. His... Dr Julian Strange is a consultant interventional cardiologist at Bristol Heart Institute, UK. His specialty and research interests are in coronary disease and include coronary angioplasty, complex PCI and chronic total occlusions (CTO) as well as advanced heart attack and cardiac arrest therapies. Read more Show less